Treating Anemia of CKD: Moving from ESAs to Oral Options
Thank you for attending this symposium. You are not required to complete this evaluation to earn CME/CE credit/contact hours for this symposium. However, your feedback is important to us, and your responses will assist us in developing future programs.
After attending this symposium, the participants in this educational activity will be able to:
- Assess the clinical implications of the recommendations of and challenges recognized by the December 2021 KDIGO Controversies Conference on Novel Anemia Therapies in CKD
- Relate the role of HIF-PHI in anemia associated with CKD to the rationale for developing therapies that targets PH inhibition
- Evaluate the clinical implications of emerging data and clinical implications of PH inhibition as a strategy to address anemia in CKD
This activity is supported by an educational grant from GSK.